P22

Overcoming immune escape of KMT2A-rearranged acute leukaemia during immune recognition

Project Summary

In P22N we investigate in Aim 1 the functional role of the KMT2A-r-induced immunosuppressive molecules CD112, CD155, TIM-3 and Gal-9 in the anti-tumour effects of allo-HSCT and CAR T cells using pharmacological and genetic approaches. In Aim 2 we will dissect the signalling and transcriptional mechanisms downstream of KMT2A-r that cause the upregulation of these immunosuppressive molecules. In Aim 3, we will validate our findings in human samples that carry KMT2A-r and xenograft models, and test novel combinatorial immunotherapies to prevent immune escape in KMT2A-r leukaemia.

  • P01Blaeschke / Zeiser
  • P02Greten
  • P03Köhler / Briquez
  • P05Apostolova / Kierdorf
  • P07Prinz
  • P08Frew
  • P10Heikenwälder / Hofmann
  • P12Duyster / Kolter
  • P14Brummer
  • P15Minguet
  • P17Ruess / Bengsch
  • P18Hoefflin / Sevenich
  • P19Hofmann / Röhlen
  • P20Metzger
  • P21Böttcher
  • P22Feuchtinger / Maas-Bauer
  • P23Ingelfinger / Sevenich
  • P24Vinnakota / Wertheimer
  • P25Pahl / Rizzi
  • S1Börries / Köttgen / Schell
  • S2Reichardt / Talvard-Balland
  • INFBinder
  • ZZeiser
  • IRTGBörries
  • P16EErlacher
  • P06EGroß
  • P04EIllert
  • P13ENyström / Kiritsi
  • P05 1.FPCabezas-Wallscheid
  • S01 1.FPSchilling